Recent Quotes (30 days)

You have no recent quotes
chg | %

AstraZeneca plc news

   Watch this stock
Showing stories 1 - 10 of about 67   

Articles published

AZN 3,945.00 -14.50 (-0.37%)
price chart
AstraZeneca India job cuts likely to hurt drug research
New Delhi: Theextensive layoffs at London-listed drug maker AstraZeneca Plc's research outfits have hit India. On 13 February, the firm's Bangalore subsidiary laid off 19 employees—15 of them middle-level and senior scientists involved in the research ...
AstraZeneca closing Montreal R&D plant
British drug maker AstraZeneca is closing its Montreal research centre as part of a global move to cut costs and improve its productivity as it warned of a tough year ahead.
AstraZeneca to cut 7300 jobs worldwide
AstraZeneca Loses Ruling Over 2018 and 2021 Crestor Patents
AstraZeneca Plc lost a U.S. appeals court bid to protect its best-selling drug, Crestor, from generic competition until as late as 2021.
Astra takes brand cancer drug straight to patients
AstraZeneca Plc is selling breast cancer drug Arimidex directly to U.S. patients, offering an option for people who want to pay for the brand instead of generic versions.
Greek Doctors Battle Hospital Superbug
The drug-resistant K. pneumoniae bacteria have a genetic mutation that allows them to evade such powerful drugs as AstraZeneca Plc's Merrem and Johnson & Johnson's Doribax. A 2010 survey found 49 percent of K. pneumoniae samples in Greece aren't ...
Top Xstrata shareholders launch fightback against �57bn mega-merger with Glencore
A proposed �57billion tie-up between mining heavyweights Glencore and Xstrata has come under fire from two major shareholders. Edinburgh-based Standard Life Investments, which has a 2.2 per cent holding in Xstrata, and Schroders, which holds 1.5 per ...
Am I in danger of losing half of my money?
Q: I have invested more than �90,000 in a stocks and shares ISA with Legal & General (L&G) by putting away a small amount each month since ISAs were launched and using up my annual allowance before the end of each financial year.
ANALYSIS: With gold prices riding high again, is now the time to sell?
Gold has seen a meteoric rise in value in the last five years. Today, prices sit at over $1,700 an ounce, more than $1,000 higher than in 2007, when prices were at roughly $650.
Commodities trader Glencore being pressed to increase bid for Xstrata
Commodities trader Glencore is expected to bow to investor pressure and raise its all-share �56bn bid for Xstrata in a bid to clinch the merger.
Glaxo readies 30 new drugs for launch as it combats cheaper competition and ...
Rival AstraZeneca last week announced it would be axeing an additional 7,300 jobs across its global operations as it looks to make cost savings.